Exencial Wealth Advisors LLC Increases Stock Holdings in Sanofi (NASDAQ:SNY)

Exencial Wealth Advisors LLC increased its holdings in shares of Sanofi (NASDAQ:SNYFree Report) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,931 shares of the company’s stock after buying an additional 3,773 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Sanofi were worth $2,682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Boston Partners grew its stake in Sanofi by 1.9% during the 4th quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after purchasing an additional 245,682 shares during the last quarter. Morgan Stanley grew its stake in Sanofi by 4.6% during the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after purchasing an additional 323,968 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Sanofi by 29.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after purchasing an additional 651,756 shares during the last quarter. Natixis Advisors L.P. grew its stake in Sanofi by 15.9% during the 3rd quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after purchasing an additional 346,563 shares during the last quarter. Finally, Brandes Investment Partners LP grew its stake in Sanofi by 64.6% during the 4th quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock valued at $88,051,000 after purchasing an additional 694,957 shares during the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on SNY shares. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Check Out Our Latest Report on SNY

Sanofi Stock Performance

Shares of SNY stock opened at $48.98 on Friday. The stock has a market cap of $123.91 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 1.54 and a beta of 0.60. The business has a 50-day simple moving average of $48.31 and a 200-day simple moving average of $48.42. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.96. The company had revenue of $11.36 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. On average, equities analysts expect that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 6th. Investors of record on Friday, May 10th were issued a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend was Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s dividend payout ratio is presently 74.37%.

About Sanofi

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Further Reading

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.